Opus Genetics Stock Today
| IRD Stock | 3.50 0.14 3.85% |
PerformanceGood
| Odds Of DistressHigh
|
Opus Genetics is trading at 3.50 as of the 26th of February 2026, a 3.85% down since the beginning of the trading day. The stock's lowest day price was 3.44. Opus Genetics has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 28th of November 2025 and ending today, the 26th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of May 2005 | Category Healthcare | Classification Health Care |
Opus Genetics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 68.96 M outstanding shares of which 664.2 K shares are currently shorted by investors with about 1.01 days to cover. More on Opus Genetics
Moving together with Opus Stock
Moving against Opus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Opus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | MBA MD | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Groupe IRD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, Opus Genetics can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Opus Genetics' use of financial leverage and reveals what portion of Opus Genetics' asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||
Opus Genetics (IRD) is traded on NASDAQ Exchange in USA and employs 18 people. Opus Genetics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 251.03 M. Opus Genetics runs under Pharmaceuticals sector within Health Care industry. The entity has 68.96 M outstanding shares of which 664.2 K shares are currently shorted by investors with about 1.01 days to cover.
Opus Genetics generates negative cash flow from operations
Check Opus Genetics Probability Of Bankruptcy
Ownership AllocationOpus Genetics owns a total of 68.96 Million outstanding shares. 30% of Opus Genetics outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Opus Ownership Details
Opus Genetics Historical Income Statement
Opus Stock Against Markets
Opus Genetics Corporate Management
| Joseph MBA | Chief Officer | Profile | |
| Jenny Kobin | Investor Officer | Profile | |
| Robert Gagnon | Chief Officer | Profile | |
| Bernhard MBA | Senior Secretary | Profile | |
| Ashwath Jayagopal | Chief Officer | Profile | |
| Bindu Manne | Head Commercialization | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Will Pharmaceuticals sector continue expanding? Could Opus diversify its offerings? Factors like these will boost the valuation of Opus Genetics. Market participants price Opus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Opus Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Opus Genetics requires distinguishing between market price and book value, where the latter reflects Opus's accounting equity. The concept of intrinsic value - what Opus Genetics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Opus Genetics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Opus Genetics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.